Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas

Dose Dense Administration of Paclitaxel and Carboplatin Combination as 1st Line Treatment in Patients With Ovarian Carcinoma

This trial will determine the feasibility and toxicity of dose intense (every 2 weeks) of paclitaxel+carboplatin combination following cytoreductive surgery in patients with stage Ic-IV ovarian cancer.

Dose dense chemotherapy has been proven beneficial in various oncological settings. It is proposed that this concept be tested in ovarian cancer, with the support of growth factors. It is hypothesized that, if feasible, dose-dense chemotherapy may be more effective.

Inclusion Criteria:

• Histologically- or cytologically- confirmed ovarian cancer requiring standard chemotherapy
• Patients have to be chemotherapy naive
• Patients may have undergone cytoreductive surgery, or this may have been omitted due to dissemination
• Age >18 years.
• Performance status (WHO) 0-2
• Life expectancy of at least three months.
• Adequate bone marrow function (Absolute neutrophil count >1000/mm^3, Platelet count>100000/mm^3, Hemoglobin>9gr/mm^3).
• Adequate liver (Bilirubin<1.5 times upper limit of normal and SGOT/SGPT<2 times upper limit of normal) and renal function (creatinine<2mg/dl)
• Informed consent

Exclusion Criteria:

• Pregnant or nursing
• Psychiatric illness or social situation that would preclude study compliance'
• Other concurrent uncontrolled illness
• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer